Edge Therapeutics (EDGE) Accused of Misleading Investors About Its Lead Product Candidate

According to a recently filed class action complaint, Edge Therapeutics (EDGE) emphasized encouraging results from its Phase 3 NEWTON 2 futility analysis of EG-1962 and expected top-line results from the NEWTON 2 study in late 2018. Despite representing to investors that Edge was operationally and financially well-positioned to advance EG-1962 through key clinical milestones, including the company's Phase 3 NEWTON 2 study, its drug did not perform as well as anticipated. On March 28, 2018, Edge revealed that it was stopping its NEWTON 2 study of EG-1962 because it had only a small chance of meeting its primary endpoint. On this news, Edge's stock price fell $14.28 per share, or over 91%, to close at $1.31 per share on March 28, 2018, and continues to decline.

Edge Therapeutics (EDGE) Shareholders Have Legal Options

If you would like more information about your rights and potential remedies, contact attorney Lauren Levi, at Llevi@robbinsllp.com or via the shareholder information form below.